3 Tanking Marijuana Stocks That Still Aren’t Worth Buying

After tanking for months, CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) may have even further to fall

| More on:
Man considering whether to sell or buy

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Marijuana stocks spent the summer of 2019 falling into the abyss. Now, some are saying they’re ready for a comeback. In August, Canopy Growth Corp ex-CEO Bruce Linton went on the record as saying he was scooping up shares in his former company’s “sale.”

More recently, Fool contributor Joey Frenette wrote that Canopy had hit a support level and had become a possible buy. Indeed, Canopy and other weed stocks have been on the rise over the past week, perhaps vindicating the bulls’ thesis.

Nevertheless, there are other weed stocks that you still shouldn’t touch with a ten-foot pole. The following are just three of them.

Tilray

Tilray Inc (NASDAQ:TLRY) is a former darling of the marijuana industry. After its IPO, it rose 755% in just under two months, making it the single biggest riser in summer 2018’s cannabis mania. More recently, however, the stock has fallen out of favour.

Thanks to the unbelievably high valuation it reached in 2018, TLRY was due for a correction. And “correct” it has, having falling 78% since its peak 2018 price. However, the stock still trades at a whopping 27 times sales despite having lost $35 million in its most recent quarter.

CannTrust

CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) is a stock that needs no introduction. After it was discovered growing pot in unlicensed rooms this past summer, it became the black sheep of the cannabis family.

As a result of its unlicensed activities, CannTrust has had holds placed on thousands of kilograms worth of its product by Health Canada.

The holds are large enough to prevent the company from earning any money this quarter, and its sales growth will likely stall when it next releases earnings. However, what happened in this most recent quarter isn’t even the worst of it.

The fact that CannTrust has been caught growing pot in unlicensed rooms not once, but twice, means that it will have extreme regulatory scrutiny on it going forward, which may force high compliance and legal costs on it for the foreseeable future.

Emerald Health Therapeutics

Emerald Health Therapeutics (TSXV:EMH) is a small-cap marijuana stock that produces a variety of CBD oil and dried cannabis products. Its focus on CBD oil is somewhat encouraging, as that product category tends to have higher margins than regular dried cannabis.

However, the stock has spent much of 2019 tanking, having fallen 60% from its peak price this year. The culprit, as with most marijuana stocks, seems to have been big losses: from 2015 to 2018, the company lost money each year.

Although the loss has been getting smaller over time, the company is still struggling to turn a profit on its cannabis operations.

On the other hand, the fact that the company’s Q2 loss of $450,000 was down from a $5 million loss a year before is very encouraging: that’s a big bite taken out of losses, and could be an indication that the company will become profitable soon.

For now, though, this stock remains one to pass on until future quarterly reports paint a better picture.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »